Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label continuation study of MT1621 (deoxycytidine + deoxythymidine) in TK2 deficiency
2018-004277-27Phase 2Active
- Sponsor
- Modis Therapeutics
- Start
- Apr 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MT1621 in thymidine kinase 2 deficiency (TK2D), sponsored by Modis Therapeutics. Primary endpoint: Safety as determined by adverse events, laboratory measurements, and electrocardiograms. Started Apr 2019; status: active.
02
Drugs
MT1621
03
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on 2018-004277-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004277-27.